Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: metformin


Gut microbiota compositions and metabolic functions in type 2 diabetes differ with glycemic durability to metformin monotherapy

March 5th 2021

There were different compositions of gut microbiota with unique microbial metabolic pathways between type 2 diabetes with and without glycemic durability to metformin monotherapy. Microbial salvage by increasing thiamine biosynthesis might be beneficial for the metformin durable group to maintain optimal glycemic control (Diabetes Research and Clinical Practice)

Categories: News, Pathology
Tags: gut microbiota, metformin, Type 2 Diabetes

Categories: Pathology
Tags: gut microbiota, metformin, Type 2 Diabetes

Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?

February 20th 2021

These effects may be considered as being to some extent similar to those produced by SGLT2is, another class of glucose-lowering agents with proven cardiorenal protection. The metabolic effects of metformin and SGLT2is may indeed have some similarities (Diabetes Care)

Categories: Medication, News
Tags: metformin

Categories: Medication
Tags: metformin

Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes

January 21st 2021

As strategy-driven, head-to-head RCTs comparing SGLT-2i, GLP-1RA, or DPP-4i with metformin (and their combination with metformin) while ensuring glycemic and weight equipoise are unlikely to become available in the future, sharing and analyzing individual-level data from already conducted RCT would help to inform the evidence for the best first-line treatment(s) in subjects with type 2 diabetes and confirm or refute our finding (Diabetes Care)

Categories: News, Research
Tags: DPP-4i, GLP-1RA, metformin, SGLT2 inhibitors

Categories: Research
Tags: DPP-4i, GLP-1RA, metformin, SGLT2 inhibitors

Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes

January 19th 2021

These results suggest that while diabetes is an independent risk factor for COVID-19-related mortality, this risk is dramatically reduced in subjects taking metformin prior to diagnosis of COVID-19, raising the possibility that metformin may provide a protective approach in this high risk population (Frontiers in Endocrinology)

Categories: Medication, News
Tags: COVID-19, metformin

Categories: Medication
Tags: COVID-19, metformin

Dose‐dependent accumulation of glucose in the intestinal wall and lumen induced by metformin as revealed by [18F]fluorodeoxyglucose PET‐MRI

November 25th 2020

Metformin dose is an independent determinant of FDG accumulation in the wall and lumen of the large intestine in individuals treated with this drug (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: metformin

Categories: Medication
Tags: metformin

Metformin Treatment: A Potential Cause of Megaloblastic Anemia in Patients with Type 2 Diabetes Mellitus

October 21st 2020

Periodical dosing of vitamin B12 should be performed in the case of patients with Type 2 Diabetes Mellitus treated with metformin, especially if they associate anemia and/or peripheral diabetic polyneuropathy (Diabetes, Metabolic Syndrome and Obesity)

Categories: Medication, News
Tags: anaemia, metformin, Type 2 Diabetes

Categories: Medication
Tags: anaemia, metformin, Type 2 Diabetes

Metformin use in prediabetes: is earlier intervention better?

October 11th 2020

The largest reductions in both incidence of diabetes and FPG occurred in prediabetic persons with a higher level of FPG at baseline. Metformin was able to stabilise insulin sensitivity and was more effective in persons with more pronounced IFG (Acta Diabetologica)

Categories: Medication, News
Tags: metformin

Categories: Medication
Tags: metformin

Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial

October 6th 2020

We found several maternal glycaemic and neonatal adiposity benefits in the metformin group. Along with reduced maternal weight gain and insulin dosage and improved glycaemic control, the lower adiposity and infant size measurements resulted in fewer large infants but a higher proportion of small-for-gestational-age infants (The Lancet Diabetes & Endocrinology)

Categories: Gestational, News
Tags: metformin, Type 2 Diabetes

Categories: Gestational
Tags: metformin, Type 2 Diabetes

Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study

September 28th 2020

Real-life population-based data suggest a positive effect of metformin on depression rates. This evidence should be used in guiding prescriptions for patients with type 2 diabetes who are at risk for developing depression, including those with prior depression or anxiety and patients with a family history of depression (Diabetes Care)

Categories: News, Psychological
Tags: metformin

Categories: Psychological
Tags: metformin

Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial

September 27th 2020

Eighteen months of metformin treatment in combination with insulin compared with insulin alone increased early drop in OBP indicating an adverse effect of metformin on CAN independent of vitamin B12, MMA HbA1c (Cardiovascular Diabetology)

Categories: Medication, News
Tags: hypotension, insulin, metformin, Type 2 Diabetes

Categories: Medication
Tags: hypotension, insulin, metformin, Type 2 Diabetes

Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial

September 18th 2020

We found several maternal glycaemic and neonatal adiposity benefits in the metformin group. Along with reduced maternal weight gain and insulin dosage and improved glycaemic control, the lower adiposity and infant size measurements resulted in fewer large infants but a higher proportion of small-for-gestational-age infants (The Lancet Diabetes & Endocrinology)

Categories: Gestational, News
Tags: metformin, Type 2 Diabetes

Categories: Gestational
Tags: metformin, Type 2 Diabetes

Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial

September 17th 2020

We found several maternal glycaemic and neonatal adiposity benefits in the metformin group. Along with reduced maternal weight gain and insulin dosage and improved glycaemic control, the lower adiposity and infant size measurements resulted in fewer large infants but a higher proportion of small-for-gestational-age infants (The Lancet Diabetes & Endocrinology)

Categories: Gestational, News
Tags: metformin, Type 2 Diabetes

Categories: Gestational
Tags: metformin, Type 2 Diabetes

Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes

September 7th 2020

Overall, the improved postprandial blood glucose levels and increase in incretins observed in the absence of changes in insulin sensitivity and gluconeogenesis, support an enteroinsular mechanistic pathway in youth with type 2 diabetes treated with short-term metformin (Diabetologia)

Categories: Medication, News
Tags: incretin, metformin, Type 2 Diabetes

Categories: Medication
Tags: incretin, metformin, Type 2 Diabetes

Efficacy of once-weekly semaglutide vs empagliflozin added to metformin in type 2 diabetes: patient-level meta-analysis

August 26th 2020

This indirect comparison suggests that OW semaglutide 1 mg provides superior reductions in HbA1c and body weight vs OD empagliflozin 25 mg in patients with T2D when added to metformin monotherapy (Journal of Clinical Endocrinology & Metabolism)

Categories: Medication, News
Tags: Empagliflozin, metformin, semaglutide, Type 2 Diabetes

Categories: Medication
Tags: Empagliflozin, metformin, semaglutide, Type 2 Diabetes

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study

August 18th 2020

Metformin use is associated with early risk of anemia in individuals with type 2 diabetes, a finding consistent across two RCTs and replicated in one real-world study (Diabetes Care)

Categories: Medication, News
Tags: anaemia, metformin, Type 2 Diabetes

Categories: Medication
Tags: anaemia, metformin, Type 2 Diabetes

Comparative effectiveness of gliclazide modified release vs sitagliptin as second‐line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes

August 9th 2020

In this real‐world study, second‐line gliclazide MR was more effective than sitagliptin in reducing HbA1c, with similar durability and persistence and low rates of hypoglycaemic events, in individuals with type 2 diabetes on metformin treatment and HbA1c above the target of 7.0% (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: gliclazide, metformin, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: gliclazide, metformin, sitagliptin, Type 2 Diabetes

Relationship between metformin therapy and risk of colorectal cancer in patients with diabetes mellitus: a meta-analysis

August 7th 2020

Metformin therapy is associated with a significantly reduced risk of colorectal disease in patients with diabetes, and it is necessary to conduct larger, more standardized clinical studies to verify this conclusion (International Journal of Colorectal Disease)

Categories: Medication, News
Tags: CRC, metformin

Categories: Medication
Tags: CRC, metformin

Evaluating the impact of AMPK activation, a target of metformin, on risk of cardiovascular diseases and cancer in the UK Biobank: a Mendelian randomisation study

August 4th 2020

This study provides some genetic evidence that AMPK activation by metformin may protect against cardiovascular disease and cancer, which needs to be confirmed by randomised controlled trials (Diabetalogia)

Categories: Medication, News
Tags: metformin

Categories: Medication
Tags: metformin

Diabetes medications with cardiovascular protection as we enter a new decade

June 10th 2020

Can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives? (ABCD)

Categories: Medication, News
Tags: GLP1, metformin, pioglitazone, SGLT2 inhibitors

Categories: Medication
Tags: GLP1, metformin, pioglitazone, SGLT2 inhibitors

What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient

May 19th 2020

This study identified patients’ phenotypic characteristics that may have the potential to influence individual treatment response. Accounting for these characteristics in clinical treatment decisions may facilitate individualised prescribing by being able to select the right drug for the right patient (Diabetes Therapy)

Categories: Genetics, News
Tags: metformin, phenotypic, Type 2 Diabetes

Categories: Genetics
Tags: metformin, phenotypic, Type 2 Diabetes
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

AstraZenecaSanofi DiabetesNapp DiabetesNovo Nordisk

Silver Sponsors

About Ascensia Diabetes CareAmgenAbbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 Empagliflozin exenatide GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes USA Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership